Welcome!

News Feed Item

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
http://www.reportlinker.com/p02003228/Frontier-Pharma-Systemic-Lupus-Erythematosus---Identifying-and-Commercializing-First-in-Class-Innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

Summary

The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug's performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape.

A growing understanding of the signaling pathways underlying SLE pathophysiology including, but not limited to, B cells, T cells and intracellular kinases, is translating into a higher number of novel, and more importantly, first-in-class targeted therapeutics entering the developmental pipeline. In particular, a high level of investment in the development of cytokine-blocking strategies is evident, as therapies targeting the interferon pathway are relatively common in the pipeline.

Scope

- The report analyzes the market for SLE therapeutics and the pipeline products in that market, with particular emphasis on first-in-class programs.
- A brief introduction to SLE, including symptoms, pathophysiology, disease scoring indices and overview of pharmacotherapy
- In-depth analysis and literature review on marketed products, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses, based on published clinical trials, as well as a reference table of drugs in terms of safety and efficacy
- Overview of how innovation products are contributing to the market for SLE therapeutics
- Comprehensive review of the pipeline for first-in-class therapies, which is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes
- The changing molecular target landscape between market and pipeline, and, in particular, focal points of innovation
- First-in-class molecular targets, highlighting early-stage programs for which clinical utility has yet to be evaluated, as well as an in-depth literature review on novel molecular targets

Reasons to buy

The report will assist the business development strategies of companies that wish to develop novel therapies with improved benefits to existing treatments. It will also be of interest to companies seeking to expand their pipeline portfolio through licensing agreements and co-development deals. Primarily, the report will allow clients to identify and understand market opportunities and the emerging competitive environment. It will also allow you to -
- Understand the SLE pipeline and the factors which indicate that it is becoming more innovative
- Understand the overall focal shifts in therapeutic molecular targets for the treatment of SLE
- Understand the distribution of the pipeline programs by phase of development, molecule type and molecular target
- Identify the list of first-in-class programs that are potentially open to deal-making opportunities
- Understand the first-in-class developmental programs and gauge the current clinical effectiveness based on animal models

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 The Case for Innovation in Systemic Lupus Erythematosus 7
2.2 Growing Opportunities for Biologic Products 7
2.3 Diversification of Molecular Targets 7
2.4 Innovative First-in-Class Product Developments Remain Attractive 8
2.5 Changes in the Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications 8
2.6 Sustained Innovation 8
3 Systemic Lupus Erythematosus 9
3.1 Disease Overview 9
3.2 Epidemiology 9
3.3 Disease Pathophysiology 10
3.4 Disease Symptoms 10
3.5 Environmental and Genetic Predisposition 11
3.6 Diagnosis 11
3.7 Disease Severity Assessments 12
3.7.1 PGA 12
3.7.2 SLEDAI 12

3.7.3 BILAG 13
3.7.4 SRI 13
3.8 Lupus Nephritis 13
3.9 Pharmacotherapy Algorithm 14
4 Clinical and Commercial Landscape 16
4.1 Corticosteroids 16
4.2 Antimalarials 16
4.3 Cytotoxic Chemotherapy 16
4.4 Biologics 17
4.4.1 Benlysta (belimumab) 17
4.5 Comparative Strengths and Weaknesses of Traditional Therapeutics 19
4.5.1 Corticosteroids vs Cytotoxic Therapeutics 19
4.5.2 Comparison of Immunosuppressants: Cyclosporine vs Azathioprine or Cyclophosphamide 21
4.5.3 Cyclophosphamide vs Azathioprine 23
4.5.4 Cyclophosphamide vs Mycophenolate Mofetil 23
4.5.5 Mycophenolate Mofetil vs Azathioprine 23
4.5.6 Biologics vs Immunosuppressants 25
4.6 Current Unmet Needs in the Systemic Lupus Erythematosus Market 27
5 Assessment of Pipeline Product Innovation 28
5.1 Overview of Pipeline Products for Systemic Lupus Erythematosus 28

5.2 Frequently Targeted Molecular Target Families 29
5.3 Comparative Distribution of Programs between the Systemic Lupus Erythematosus Market and Pipeline by Therapeutic Target Family 30
5.4 Comparative Efficacy and Safety of Pipeline Programs 31
5.5 Comparative Distribution of Programs with First-in-Class and Established Targets 33
5.6 Pipeline Programs Targeting Established Molecular Targets 35
5.7 First-in-class Pipeline Programs with Novel Molecular Targets 37
6 First-in-Class Target and Pipeline Program Evaluation 39
6.1 Cytokines and Receptors 39
6.1.1 Pipeline Programs Targeting IFN-? 39
6.1.2 Pipeline Programs Targeting CD74 43
6.1.3 Pipeline Programs Targeting B7 Related Protein 44
6.1.4 Pipeline Programs Targeting IL-21 46
6.1.5 Pipeline Programs Targeting IL-17 49
6.1.6 Pipeline Programs Targeting High Mobility Protein Box 1 51
6.1.7 Pipeline Programs Targeting APRIL 53
6.2 B and T Cell Antigens 55
6.2.1 Pipeline Programs Targeting CD4 55
6.2.2 Pipeline Programs Targeting CD40L 57
6.2.3 Pipeline Programs which Target Fc?R2b (CD32b) 60
6.2.4 Pipeline Programs which Target CD19 62
6.2.5 Pipeline Programs which Target CD22 64
6.3 Intracellular Kinase 67

6.3.1 Pipeline Programs which Target Spleen Tyrosine Kinase 67
6.4 Others 70
6.4.1 Pipeline Programs which Target Immunoproteasome subunit 7 (IMP7) 70
6.4.2 Pipeline Programs which Target ILT-7 71
7 Conclusions 72
8 Deals and Strategic Consolidations 74
8.1 Licensing Agreements 74
8.2 Co-development Deals 76
8.2.1 First-in-Class Developmental Programs Not Involved in Co-development Deals or Licensing Deals 78
9 Appendix 79
9.1 References 79
9.2 Abbreviations 88
9.3 Methodology 89
9.4 Contact Us 89
9.5 Disclaimer 89

List of Tables

Table 1: SLEDAI Index 12
Table 2: Classification of Lupus Nephritis 14
Table 3: Pipeline, Global, First-in-class Modulators of B7-Related Protein, Scientific Assessment 44
Table 4: Pipeline, Global, First-in-Class Modulators of IL-17, Scientific Assessment 49
Table 5: Pipeline, Global, First-in-class Modulators of APRIL, Scientific Assessment 53
Table 6: Pipeline, Global, First-in-class Modulators of CD4, Scientific Assessment 55
Table 7: Pipeline, Global, First-in-Class Modulators of Fc?R2b, Scientific Assessment 60
Table 8: Pipeline, Global, First-in-Class Modulators of CD19, Scientific Assessment 62
Table 9: Pipeline, Global, First-in-Class Modulators of CD22, Scientific Assessment 65
Table 10: Pipeline, Global, First-in-Class Modulators of Immunoproteasome Subunit 7, Scientific Assessment 70
Table 11: Pipeline, Global, First-in-Class Modulators of Immunoproteasome Subunit 7, Pipeline Development 71
Table 12: Pipeline, Global, First-in-Class Modulators of Immunoglobulin-Like Transcript 7, Pipeline Development 71

List of Figures

Figure 1: SLE, Treatment Algorithm 14
Figure 2: Systemic Lupus Erythematosus, Global, Marketed Products 18
Figure 3: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety of Marketed Products 19
Figure 4: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 20
Figure 5: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 22
Figure 6: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 24
Figure 7: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety 26
Figure 8: Systemic Lupus Erythematosus, Global Pipeline Overview 28
Figure 9: Systemic Lupus Erythematosus, Global, Pipeline and Marketed Products 30
Figure 10: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety of Pipeline Programs Relative to Benlysta (belimumab) 32
Figure 11: Systemic Lupus Erythematosus, Global, Pipeline, First-in-class Products 34
Figure 12: Systemic Lupus Erythematosus, Global, Pipeline, Programs with Established Molecule Targets 36
Figure 13: Systemic Lupus Erythematosus, Global, Pipeline, First-in-class Programs 38
Figure 14: Pipeline, Global, First-in-Class IFN-? Inhibitors, Scientific assessment 41
Figure 15: Pipeline, Global, First-in-Class IFN-? Inhibitors, Pipeline Development 42
Figure 16: Pipeline, Global, First-in-Class CD74 Inhibitors, Pipeline Development 43
Figure 17: Pipeline, Global, First-in-Class Modulators of B7-Related Protein, Pipeline Development 45
Figure 18: Pipeline, Global, First-in-class modulators of IL-21, Scientific Assessment 47
Figure 19: Pipeline, Global, First-in-class Modulators of IL-21, Pipeline Development 48
Figure 20: Pipeline, Global, First-in-Class Modulators of IL-17 , Pipeline Development 50
Figure 21: Pipeline, Global, First-in-Class High Mobility Box Protein 1 Inhibitors, Pipeline Development 52

Figure 22: Pipeline, Global, First-in-class Modulators of APRIL, Pipeline Development 54
Figure 23: Pipeline, Global, First-in-class Modulators of CD4, Pipeline Development 56
Figure 24: Pipeline, Global, First-in-Class Modulators of CD40L, Scientific Assessment 58
Figure 25: Pipeline, Global, First-in-Class Modulators of CD40L, Pipeline Development 59
Figure 26: Pipeline, Global, First-in-Class Modulators of Fc?R2b, Pipeline Development 61
Figure 27: Pipeline, Global, First-in-Class Modulators of CD19, Pipeline Development 63
Figure 28: Pipeline, Global, First-in-Class Modulators of CD22, Pipeline Development 66
Figure 29: Pipeline, Global, First-in-Class Modulators of Spleen Tyrosine Kinase, Scientific Assessment 68
Figure 30: Pipeline, Global, First-in-Class modulators of Spleen Tyrosine Kinase, Pipeline Development 69
Figure 31: Systemic Lupus Erythematosus, Global, Licensing Agreements, 2006–2013 (October) 75
Figure 32: Systemic Lupus Erythematosus, Global, Co-development deals, 2006–2013 (October) 77
Figure 33: Systemic Lupus Erythematosus, Global, First in-Class Programs Not Involved in Co-development or Licensing Deals 78

To order this report: Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
http://www.reportlinker.com/p02003228/Frontier-Pharma-Systemic-Lupus-Erythematosus---Identifying-and-Commercializing-First-in-Class-Innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that ContentMX, the marketing technology and services company with a singular mission to increase engagement and drive more conversations for enterprise, channel and SMB technology marketers, has been named “Sponsor & Exhibitor Lounge Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York. “CloudExpo is a great opportunity to start a conversation with new prospects, but what happens after the...
In the rush to compete in the digital age, a successful digital transformation is essential, but many organizations are setting themselves up for failure. There’s a common misconception that the process is just about technology, but it’s not. It’s about your business. It shouldn’t be treated as an isolated IT project; it should be driven by business needs with the committed involvement of a range of stakeholders.
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
SYS-CON Events announced today that EastBanc Technologies will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. EastBanc Technologies has been working at the frontier of technology since 1999. Today, the firm provides full-lifecycle software development delivering flexible technology solutions that seamlessly integrate with existing systems – whether on premise or cloud. EastBanc Technologies partners with p...
SYS-CON Events announced today that AppNeta, the leader in performance insight for business-critical web applications, will exhibit and present at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. AppNeta is the only application performance monitoring (APM) company to provide solutions for all applications – applications you develop internally, business-critical SaaS applications you use and the networks that deli...
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. Commvault can ensure protection, access and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his general session at 18th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Part...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, will discuss the importance of WebRTC and how it enables companies to fo...
As machines are increasingly connected to the internet, it’s becoming easier to discover the numerous ways Industrial IoT (IIoT) is helping to shape the business world. This is exactly why we have decided to take a closer look at this pervasive movement and to examine the desire to connect more things! Now if you need a refresher on IIoT and how it is changing the world, take a moment and listen to Greg Gorbach with ARC Advisory Group. Gorbach believes, "IIoT will significantly change the worl...
SYS-CON Events announced today the Docker Meets Kubernetes – Intro into the Kubernetes World, being held June 9, 2016, in conjunction with 18th Cloud Expo | @ThingsExpo, at the Javits Center in New York, NY. Register for 'Docker Meets Kubernetes Workshop' Here! This workshop led by Sebastian Scheele, co-founder of Loodse, introduces participants to Kubernetes (container orchestration). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, participants learn ...
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discuss how businesses can gain an edge over competitors by empowering consumers to take control through IoT. We'll cite examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He'll also highlight how IoT can revitalize and restore outdated business models, making them profitable...
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device. For more information, please visit https://www.mangoapps.com/.
In his session at 18th Cloud Expo, Andrew Cole, Director of Solutions Engineering at Peak 10, will discuss how the newest technology advances are reducing the cost and complexity of traditional business continuity and disaster recovery solutions. Attendees will: Learn why having a full disaster recovery strategy is more important now than ever before Explore the key drivers of a successful disaster recovery solution Achieve measurable operational and business value from a disaster recovery ...
SYS-CON Events announced today the How to Create Angular 2 Clients for the Cloud Workshop, being held June 7, 2016, in conjunction with 18th Cloud Expo | @ThingsExpo, at the Javits Center in New York, NY. Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified. Now it’s a component-based well-performing framework. The immersive one-day workshop led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and ...